Despite remarkable progress in the last decade, metastatic prostate cancer (mPCa) remains
incurable. The approval of PARP inhibitors (PARPis) represents a milestone in this field …

Preclinical and clinical studies have suggested potential synergies of combining poly (ADP-
ribose) polymerase (PARP) inhibitors and novel hormonal therapies (NHT) for patients with …

Patients with advanced prostate cancer (PCa) invariably develop resistance to anti-
androgen therapy and taxane-based chemotherapy. Glucocorticoid receptor (GR) has been …

Prostate cancer (PCa) remains both a global health burden and a scientific challenge. We
present a review of the molecular targets driving current drug discovery to fight this disease …

Abstract Treatment intensification with androgen deprivation therapy (ADT) and androgen
receptor pathway inhibitors (ARPi) have led to improved survival in advanced prostate …

Background PARP inhibitors (PARPis) are effective treatment options for patients with
metastatic castration-resistant prostate cancer (mCRPC) as single agents or in combination …

Prostate cancer (PCa) is one of the most common male genitourinary system malignancies.
Despite the significant benefits of anti-PD-L1 immune checkpoint inhibitor therapy in other …

Aberrations in the homologous recombination repair (HRR) pathway in prostate cancer
(PCa) provide a unique opportunity to develop therapeutic strategies that take advantage of …

Simple Summary This review explores the evolution of treatment strategies for metastatic
castration-sensitive prostate cancer, emphasizing the benefits of early treatment …

The nuclear hormone family of receptors regulates gene expression. The androgen receptor
(AR), upon ligand binding and homodimerization, shuttles from the cytosol into the nucleus …